[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:monomorphic-epitheliotropic-intestinal-t-cell-lymphoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":55,"states":56},"Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma",7,5,[8,16,22,29,35,41,48],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07382817","Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r\u002Fr CD94+ T\u002FNK Cell Neoplasms",[12],"Phase 1","RECRUITING","2026-08-26T02:18:42.501841Z","2026-05-05T02:43:29.473779Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07055477","A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)",[12],"2026-08-26T02:18:46.137046Z","2026-05-05T02:43:27.673466Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT05475925","A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas",[26],"Phase 1\u002FPhase 2","2026-08-26T02:15:28.524219Z","2026-05-05T02:43:27.068416Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT05010005","A Study of Ruxolitinib and Duvelisib in People With Lymphoma",[12],"2026-08-26T02:16:01.079019Z","2026-05-05T02:43:26.685721Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT05978141","A Registry for People With T-cell Lymphoma",[],"2026-08-26T02:16:20.336282Z","2026-05-13T02:55:06.403613Z",{"nct_id":42,"title":43,"phases":44,"status":45,"updated_at":46,"content_modified":47},"NCT07691450","Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma",[12],"NOT_YET_RECRUITING","2026-08-26T02:16:42.787115Z","2026-07-19T19:36:05.157190Z",{"nct_id":49,"title":50,"phases":51,"status":52,"updated_at":53,"content_modified":54},"NCT03690011","Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T03:05:09.265674Z","2026-05-05T02:43:27.128098Z",[],[57,61,65,68,71],{"state":58,"count":59,"slug":60},"Texas",4,"texas",{"state":62,"count":63,"slug":64},"California",3,"california",{"state":66,"count":63,"slug":67},"Florida","florida",{"state":69,"count":63,"slug":70},"Massachusetts","massachusetts",{"state":72,"count":63,"slug":73},"New York","new-york"]